Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa

Open Forum Infectious Diseases

Volumn 4, Issue 3, 2017, Pages

  Cai, Bin ^a   Echols, Roger ^b   Magee, Glenn ^c   Ferreira, Juan Camilo Arjona ^a   Morgan, Gareth ^a   Ariyasu, Mari ^a   Sawada, Takuko ^a   Nagata, Tsutae ^a  

^a SHIONOGI AND CO LTD   (Japan)

^b Clinical Development and Medical Affairs LLC   (United States)

^c Premier Research Service Inc ^*  (United States)

Author keywords

carbapenem resistance; CRE; Gram negative; in hospital mortality; length of stay; nonfermenters

Indexed keywords

EID: 85129361876     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/OFID/OFX176     Document Type: Article

References (27)

1. Kim YJ, Jun YH, Kim YR, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. BMC Infect Dis 2014; 14:161.
2. Magiorakos AP, Suetens C, Monnet DL, et al. The rise of carbapenem resistance in Europe: just the tip of the iceberg? Antimicrob Resist Infect Control 2013; 2:6.
3. Ny P, Nieberg P, Wong-Beringer A. Impact of carbapenem resistance on epidemiology and outcomes of nonbacteremic Klebsiella pneumoniae infections. Am J Infect Control 2015; 43:1076-80.
4. Xu A, Zheng B, Xu YC, et al. National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin Microbiol Infect 2016; 22(Suppl 1):S1-8.
5. US Department of Health and Human Services, Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed January 10, 2017.
6. European Centre for Disease Prevention and Control. Evidence brief: update on the spread of carbapenemase-producing Enterobacteriaceae in Europe - summary of the May 2015 expert assessment. Available at: http://ecdc.europa.eu/en/eaad/antibiotics-news/Documents/antimicrobial-resistance-EuSCAPE-Evidence-Brief.pdf. Accessed January 31, 2017.
7. European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017. Available at: http://ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-europe-2015.pdf. Accessed January 31, 2017.
8. Sisto A, D'Ancona F, Meledandri M, et al. Carbapenem non-susceptible Klebsiella pneumoniae from Micronet network hospitals, Italy, 2009 to 2012. Euro Surveill 2012; 17: pii: 20247.
9. Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data r eported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013; 34:1-14.
10. US Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Disease, Division of Healthcare Quality Promotion. Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE) - November 2015 update CRE Toolkit. Available at: https://www.cdc.gov/hai/pdfs/cre/cre-guidance-508.pdf. Accessed January 10, 2017.
11. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. Korean J Intern Med 2012; 27:128-42.
12. European Centre for Disease Prevention and Control. Carbapenem-resistant Acinetobacter baumannii in healthcare settings - 8 December 2016. Stockholm: ECDC; 2016. Available at: http://ecdc.europa.eu/en/publications/Publications/8-Dec-2016-RRA-Acinetobacter%20baumannii-Europe.pdf. Accessed January 31, 2017.
13. Gniadek TJ, Carroll KC, Simner PJ. Carbapenem-resistant non-glucose-fermenting gram-negative bacilli: the missing piece to the puzzle. J Clin Microbiol 2016; 54:1700-10.
14. Labarca JA, Salles MJ, Seas C, Guzmán-Blanco M. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America. Crit Rev Microbiol 2016; 42:276-92.
15. Lesho E, Chukwuma U, Sparks M, et al. Anatomic, geographic, and taxon-specific relative risks of carbapenem resistance in the health care system of the U.S. Department of Defense. J Clin Microbiol 2016; 54:1546-51.
16. Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med 2016; 11:21-6.
17. World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Published February 27, 2017. Available at: http://www.who.int/medicines/publications/global-priority-list-antibiotic-resistant-bacteria/en/. Accessed June 16, 2017.
18. Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-9.
19. Micek ST, Wunderink RG, Kollef MH, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care 2015; 19:219.
20. Premier Inc. Premier Healthcare Database: data that informs and performs. Published January 31, 2017. Available at: https://learn.premierinc.com/pharmacy-and-research/premier-healthcare-database-whitepaper. Accessed June 16, 2017.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
22. US Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Disease, Division of Healthcare Quality Promotion. Antibiotic Resistance Patient Safety Atlas summary of results. Available at: https://www.cdc.gov/hai/pdfs/patient-safety-atlas/ar-patient-safety-atlas-summary-of-results.pdf. Accessed January 10, 2017.
23. Huijskens EG, Rossen JW, Kluytmans JA, et al. Evaluation of yield of currently available diagnostics by sample type to optimize detection of respiratory pathogens in patients with a community-acquired pneumonia. Influenza Other Respir Viruses 2014; 8:243-9.
24. Kleinfauf N, Hausemann A, Kempf VAJ, Gottschalk R, Heudorf U. Burden of carpabenem-resistant organisms in the Frankfurt/Main Metropolitan Area in Germany 2012/2013 - first results and experiences after the introduction of legally mandated reporting. BMC Infect Dis 2014; 12:446.
25. Freeman R, Moore LS, Charlett A, et al. Exploring the epidemiology of carbapenem-resistant Gram-negative bacteria in west London and the utility of routinely collected hospital microbiology data. J Antimicrob Chemother 2015; 70:1212-8.
26. Brooke JS. New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen. Expert Rev Anti Infect Ther 2014; 12:1-4.
27. Sánchez MB. Antibiotic resistance in the opportunistic pathogen Stenotrophomonas maltophilia. Front Microbiol 2015; 6:658.